PHILADELPHIA, Nov. 18, 2025 /PRNewswire/ -- BlueWhale Bio, Inc., a company dedicated to transforming immune cell therapy manufacturing, today announced that its Synecta™ cell-derived nanoparticle ...
Gene therapy developers and manufacturers adopting NanoMosaic's platform gain access to enhanced FDA engagement and expedited IND/BLA review. The FDA AMT designation verifies NanoMosaic platform's ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する